Vicriviroc in Combination Treatment With an Optimized ART [antiretroviral] Regimen in Treatment-Experienced Subjects With R5/X4 HIV Infection (VICTOR-E2; Protocol No. P05057).
Phase of Trial: Phase II
Latest Information Update: 13 Jan 2014
At a glance
- Drugs Vicriviroc (Primary)
- Indications HIV infections
- Focus Registrational; Therapeutic Use
- Acronyms VICTOR-E2
- Sponsors Merck Sharp & Dohme; Schering-Plough
- 10 Jun 2017 Biomarkers information updated
- 16 Jul 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.
- 16 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.